Mucous membrane immunizing agent of polyglycol-inactivated vaccine

A technology of polyethylene glycol and mucosal immunity, which is applied in the direction of antiviral agents, antibody medical ingredients, medical preparations containing active ingredients, etc., can solve problems such as adverse reactions, and achieve enhanced immunogenicity and local mucosal immune response , improve the effect of absorption

Inactive Publication Date: 2006-10-11
FUDAN UNIV
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Studies have shown that due to the possibility of antibody enhancement in the pathogenesis of some viruses, IgG antibodies may produce adverse reactions at this stage; the injection of whole virus vaccines (such as influenza virus) for some viruses is difficult to induce local immunity Phenomenon such as reaction

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Mucous membrane immunizing agent of polyglycol-inactivated vaccine
  • Mucous membrane immunizing agent of polyglycol-inactivated vaccine

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0015] Embodiment 1 polyethylene glycol concentrates and inactivates SARS coronavirus

[0016] Pharmaceutical grade polyethylene glycol 6000 was formulated as 35% polyethylene glycol / 1.75M NaCl. Add inactivated SARS coronavirus (CGMCC No.0977) venom at a ratio of 1:5, and incubate at 4°C for 24 hours. Centrifuge at 13,000 rpm for 30 minutes. Remove the supernatant, and the precipitate is dissolved in phosphate buffer (0.01M PBS, pH7.2), and the virus is concentrated to 100 times to obtain the crude inactivated SARS coronavirus mucosal immune preparation.

Embodiment 2

[0017] Example 2 Polyethylene Glycol Concentration, Inactivation and Cracking of Influenza A Virus

[0018] Pharmaceutical grade polyethylene glycol 8000 was formulated as 30% polyethylene glycol / 1.75M NaCl. Add the inactivated lysed influenza A virus solution at a ratio of 1:4, and incubate at 4°C for 24 hours with the H3N3 Panama strain (the domestically produced strain in 2003). Centrifuge at 13,000 rpm for 30 minutes. The supernatant was removed, and the precipitate was dissolved in phosphate buffer (0.01M PBS, pH7.2) to concentrate the virus to 50 times to obtain a crude inactivated avian influenza virus mucosal immune preparation.

Embodiment 3

[0019] Embodiment 3 polyethylene glycol enhances the immunogenicity of nasal drop SARS coronavirus vaccine

[0020] Inactivated SARS coronavirus (G250) vaccine, immunization dose: 50 μg per mouse; PEG-SARS coronavirus inactivated mucosal immune preparation, immunization dose: 20 μg per mouse, immunized Balb / c mice through nasal drops respectively, Vaccines were given every 2 weeks, for a total of 4 immunizations. The mice were sacrificed 2 weeks after the fourth strong immunization, the blood was collected to separate the serum, and the trachea and lungs of the mice were lavaged with phosphate buffer. Serum and tracheal-lung lavage fluid were stored at -70°C until testing. Serum is used to detect the neutralizing antibody of anti-SARS coronavirus; trachea-lung lavage fluid is used to detect anti-SARS coronavirus IgA (indirect immunofluorescence method). The results show that the immunity of PEG-inactivated vaccine nasal drops is significantly higher than that of inactivated ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention belongs to the field of biotechnology and relates to a polyethylene glycol-inactivated vaccine mucosal immune preparation. The invention uses pharmaceutical grade polyethylene glycol to concentrate and purify the inactivated virus liquid and prepare the vaccine, and uses polyethylene glycol as an immune adjuvant to modify and link the inactivated vaccine protein to enhance the stability and immunogenicity of the vaccine. and local mucosal immune responses. Animal experiments show that the invention can prolong the residence time of the vaccine in the nasal cavity, improve nasal mucosa absorption, and have no damage to local nasal mucosa and cilia. The immune effect is significantly higher than that of the inactivated vaccine, and it is still immunogenic after half a year when stored at 4°C.

Description

technical field [0001] The invention belongs to the field of biotechnology and relates to a polyethylene glycol-inactivated vaccine mucosal immune preparation. It specifically relates to the preparation of mucosal immune agent by concentrating inactivated virus vaccine with polyethylene glycol. Background technique [0002] In order to prevent respiratory diseases caused by viral infections, such as severe acute respiratory syndrome (severe acute respiratory syndrome, SARS), viral influenza and viral avian influenza, it is very urgent to develop vaccines. In view of the fact that SARS virus and influenza virus can be cultured in tissue cells and can reach high titers, research on inactivated vaccines is the first choice at home and abroad. Studies have shown that due to the possibility of antibody enhancement in the pathogenesis of some viruses, IgG antibodies may produce adverse reactions at this stage; the injection of whole virus vaccines (such as influenza virus) for so...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K39/39A61K39/12A61P31/12
Inventor 瞿涤闻玉梅姚忻
Owner FUDAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap